Skip to main content
. 2022 Jan 31;28(4):214.e1–214.e11. doi: 10.1016/j.jtct.2022.01.019

Figure 3.

Figure 3

Humoral immunity to the SARS-CoV-2 vaccine improves over time after allo-HCT. (A) Heatmap of SARS-CoV-2 seroprofiles (IgG, IgA, and IgM SOC values against 4 SARS-CoV-2 antigens: RBD, S1, S2, and N) at T2 in allo-HCT recipients (dark blue, 3 to 6 months; yellow, 6 to 12 months; light blue, >12 months) and healthy controls (gray), and their preinfection status (black, yes; light gray, no). Patients are grouped in rows in 3 different clusters, and antibody responses are displayed in columns. (B) Principal component analysis (PCA) of SARS-CoV-2 seroprofiles (IgG, IgA, and IgM SOC values against 4 SARS-CoV-2 antigens: RBD, S1, S2, and N) at T2 of allo-HCT recipients (dark blue, 3 to 6 months; yellow, 6 to 12 months; light blue, >12 months) and healthy controls (gray), and their preinfection status (black, yes; light gray, no). Each subfigure highlights one of the clusters previously defined in the heatmap—cluster 1 (top), cluster 2 (middle) and cluster 3 (bottom)—and patients not belonging to the cluster of interest are shown in light gray. (C) Results from univariable (light blue) and multivariable (black) linear regression predicting log10 of the sum S1 value at T2 in allo-HCT recipients and healthy controls.